Charles A. McWherter

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

Gideon M. Hirschfield, Christopher L. Bowlus, Marlyn J. Mayo et al. · New England Journal of Medicine · 2024 · 235 citations

Medicine, Pharmacology, Pharmacotherapy +10

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

David Jones, Pol Boudes, Mark G. Swain et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 186 citations

Medicine, Pharmacology, Pharmacotherapy +12

Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase

David A. Rudnick, Charles A. McWherter, Warren J. Rocque et al. · Journal of Biological Chemistry · 1991 · 148 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Genetic studies reveal that myristoylCoA:protein N‐myristoyltransferase is an essential enzyme in <i>Candida albicans</i>

Robin A. Weinberg, Charles A. McWherter, Sandra K. Freeman et al. · Molecular Microbiology · 1995 · 123 citations

Life Sciences, Genetics, Microbiology +16

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein et al. · Hepatology · 2023 · 113 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13